Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Inclusion Criteria:

Diagnosis of either atopic dermatitis or psoriasis with mild to moderate lesions involving 1% - 25% of total body surface area
Candidate for topical treatment of atopic dermatitis or psoriasis
Negative pregnancy test for females of childbearing potential

Exclusion Criteria:

Systemic pharmacotherapy or phototherapy for treatment of atopic dermatitis or psoriasis
Erythrodermic, guttate or generalized pustular psoriasis
Treatment of systemic retinoids, corticosteroids or immunosuppressive agents within 4 weeks of baseline visit
Treatment with high potency topical steroids, vitamin D analogs, keratolytics, coal tar, phototherapy, calcineurin inhibitors, or antihistamines within 2 weeks of baseline visit
UV or Dead Sea therapy within 4 weeks of baseline visit
Treatment with a biologic agent (monoclonal antibody) within 30 days or 5 times its circulating half-life (whichever is longer) prior to baseline visit
Atopic dermatitis triggered by environmental allergen or irritant
Contact dermatitis or drug-induced skin reactions
Systemic or skin infection requiring antimicrobial therapy
Systemic chemotherapy or radiotherapy within 4 weeks of baseline visit
Immunocompromise of any cause
Pregnancy, lactation or inadequate contraception
Active drug or alcohol dependence
Significant acute or chronic medical, neurological or psychiatric illness that would compromise subject's safety